Stifel analyst Alex Thompson notes that Amgen (AMGN) announced positive topline results for the Phase 3 on-body infusion study of Tepezza achieving a 77% rate of proptosis response, which comes in higher on both an absolute and placebo-adjusted basis compared to Viridian Therapeutics’ (VRDN) elegrobar. However, with elegrobart’s subcutaneous injection profile versus on-body infusion, the firm sees a path towards differentiation in the market, says the analyst, who has a Buy rating on Viridian shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Evercore cuts Viridian price target, removes from ‘Tactical Outperform’ list
- Viridian Therapeutics price target lowered to $37 from $44 at Wedbush
- Viridian Therapeutics price target lowered to $20 from $29 at Wells Fargo
- Viridian Therapeutics price target lowered to $36 from $41 at Goldman Sachs
- Viridian Therapeutics price target lowered to $22 from $34 at H.C. Wainwright